Webinar on Global Supply Chain Integrity Focusing on Track & Trace System for Pharmaceuticals

APEC Centre of Excellence in Global Supply Chain Integrity

Taylor's University August 10th, 2022

Track & Trace System: Implementation Plan & Updates

Pharmaceutical Services Programme, Ministry of Health Malaysia


Mohd Azuwan Bin Mohd Zubir Senior Principal Assistant Director Pharmacy Policy & Strategic Planning Division, MOH Malaysia

Presentation Outline

- 1. Introduction: What is Traceability or Track & Trace?
- 2. Control of Pharmaceutical Products in Malaysia, Problem Statement: Challenges in Pharmaceutical Supply Chain
- 3. Rationale for Track & Trace Implementation
- 4. Centralized National Track & Trace Approach: Policy, Process & Technology Consideration
- 5. Track & Trace MOH Malaysia Perspective
- 6. Implementation Plan & Progress
- 7. Proof of Concept (POC): Vaccine Management System (VMS)
- 8. Pharmaceutical Track & Trace System Pilot Project
- 9. Way Forward

Introduction: What is Traceability or Track & Trace?


"is the ability to <u>track forward</u> the movement through specified stage(s) of the extended supply chain and <u>trace backward</u> the history, application or location of that which is under consideration" ...generally using documented & recorded "unique" identification. - WHO



Pharmaceutical Serialization & Traceability

Centralised Database





Control of Pharmaceutical Products in Malaysia

Current Situation

Acts & Regulations

- 1. Registration of Pharmacists Act 1951(revised 1989) & Regulations
- 2. Poisons Act 1952 (revised 1989) & Regulations
- 3. Sale of Drugs Act 1952 (revised 1989) & Control of Drugs and Cosmetics Regulations 1984 (revised 2006)
- 4. Dangerous Drugs Act 1952 (revised 1980) & Regulations
- 5. Medicines (Advertisement and Sale) Act 1956 (revised 1983) & Regulations

All pharmaceutical products must be registered with the Drug Control Authority (DCA) before it is marketed and sold to consumers

Registration Number

1985 - 2005

Control over the sales of pharmaceutical products

Registered pharmaceutical product is given a specific registration number (eg; MAL 20001564A) to be printed on the label or its packaging



Security Label (Hologram)

2005 - present

Hologram was introduced in 2005 with an extensive safety features that can be verified by both consumers and pharmacy enforcement officers

All registered products must display product registration number and hologram security label on its packaging

Regulation 29 Control of Drugs and Cosmetics Regulations 1984

Current Situation Product ABC ABC Hydrochloride 100mg 100 x 10s tablets Active Ingredient (s) and Strength (s) **FarmaTagTM** (2019 – 2023) **Product ABC** ABC Hydrochloride 100mg **Product Registration** Number **Security Label 1985** till present (Hologram) Meditag[™] 3 Meditag[™] 4 2005 till present (2012)(2017)MAL20031231A Dosage Form and Pack Size 100 x 10's tablets Keep out of the react of children DCA Labelling Requirements 'Controlled medicine'/ Ubat Terkawal (For Scheduled Poison only) Controlled Medicine Product ABC ABC Hydrochloride 100mg Storage Condition Route of Administration Meditag™ Meditag[™] 2 Specific Labelling (2005)(2006)Name and Address of Manufacturer XYZ PTY LTD Batch number Product Registration Holder Date of Manufacture Manufacturing Date Expiry Date Expiry Date Name and Address of PRH

MeditagTM (2005 – 2019)

Appendix 19 General Labelling Requirement, Drug Registration Guidance Document (DRGD), January 2022, National Pharmaceutical Regulatory Agency (NPRA)

Problem Statement: Challenges in Pharmaceutical Supply Chain







Another falsified batch of Roche's cancer drug Avastin has been discovered by

Four boxes of the product - in Bulgarian packaging - were found at an as-yet unidentified Dutch pharmaceutical wholesaler, according to an alert issued by the Dutch Health Care Inspectorate IGJ (Inspectie voor Gezondhei

The falsification came to light when a wholesaler scanned a box in of the new system of safety features that has been in force since F 2019. When scanning, the wholesaler was notified of a possible co and this is one of the first times on public record that the veri in place as part of the Falsified Medicines Directive (FMD) in February has protected patients from being exposed to potentially fake drugs.

Author

daripa nitroso

WHO says fake cancer drug Iclusig has been "traded globally"



Falsified copies of leukaemia drug Iclusig are being traded around the world and have reached the patient level in Asian markets, says the World Health

had also

Substandard & Falsified Medicine

nat are

the batch number PR0834170. Neither of the batch numbers is genuine according to Iclusig's manufacturers.

Health Ministry: Influenza A vaccine supply sufficient, no need to worry

By Dawn Chan - January 12, 2020 @ 4:28pm

There is no shortage of the vaccine. Pharmaniaga has already assured us that there would not be any disruption in terms

Four ways to build supply-chain resilience

Supply-chain resilience requires four elements: end-to-end transparency, routine stress-testing and reassessment, reduced exposure to shocks, and supply-chain resilience on the executive agenda.

End-to-end transparency

Efficient Supply Chain

ility into the business practices of suppliers and suppliers' suppliers can be a

ies. Major consumer brands have been accused of unfair labor have been found to have used child labor.

by tier to have an end-to-end view of the supply chain and

identify vulnerabilities. It's also vital to have a clear understanding of exposures beyond supply,

HSA Stops Supply of Eight Brands of Ranitidine Products in Singapore

Eight brands of ranitidine medicines have been found to contain trace amounts of a nitrosamine impurity. Nnitrosodimethylamine (NDMA), which are above the internationally acceptable level. As a precautionary measure, the Health Sciences Authority (HSA) is stopping the sale and supply of the affected ranitidine medicines at clinics, hospitals and pharmacies [see Table A for full list of medicines].

Kenyataan Akhbar KPK 29 Mac 2019 -Produk Losartan yang ditarik Balik di Singapura Serta Situasi di Pasaran Malaysia





Product Recalls

Why Track & Trace?

Authority

Industry

Healthcare Facilities

Consumer



Strengthening Regulatory Activities through Global Standards

Good governance in medicine, Protecting consumer & industries from substandard and falsified product



Cost Optimization & Operational Efficiency

Reduce product waste due to obsolescence, Improving product recall efficiency and effectiveness, Improving transaction accuracy, healthcare transformation



Enhancing Ecosystem of Pharmaceutical Sector

Bolster the pharmaceutical export growth, Improve efficiency inventory assets & associated costs, Strengthening multiple stakeholders' collaboration



Improve Patient Safety

Reducing medication errors; improve patient safety, consumer empowerment



Visibility




Product Safety




Supply Chain Security

Rationale of Implementation





Track & trace mandate by NRAs



Meningkatkan Kesiapsiagaan untuk Mengendali Krisis Kesihatan

Perkhidmatan penjagaan kesihatan akan diperkukuh dengan penyediaan fasiliti, perkhidmatan farmaseutikal, personel kesihatan dan kelengkapan perubatan yang lebih baik untuk meningkatkan tahap kesiapsiagaan dalam mengendali krisis kesihatan. Kapasiti makmal kemahiran klinikal akan ditambah baik bagi meningkatkan kecekapan personel kesihatan dalam menyediakan rawatan berkualiti terbaik. Langkah keselamatan di makmal klinikal juga akan ditambah baik untuk mematuhi sepenuhnya piawaian yang ditetapkan oleh WHO bagi memastikan keselamatan personel. Tambahan pula, personel kesihatan dan kelengkapan perubatan bagi pasukan respons kecemasan awam pelbagai bahaya akan diperkukuh di beberapa pintu masuk terpilih, terutama di Lapangan Terbang Antarabangsa Kuala Lumpur, Sepang, Semua jabatan kecemasan, terutama di hospital negeri akan dilengkapkan dengan peralatan yang lebih baik untuk meningkatkan kecekapan penyampaian perkhidmatan. Di samping itu, sistem track and trace farmaseutikal akan diperkenal untuk memastikan bekalan ubat-ubatan yang mencukupi dan pengedaran yang cekap ke semua fasiliti penjagaan kesihatan. Sistem ini juga akan berfungsi untuk memeriksa ketulenan ubat.







Centralized National Track & Trace Approach

Policy Consideration

Government issuing **mandates** (laws, regulations, directives etc.) that define, govern, and establish an appropriate incentive structure for the track and trace program. The mandates should address **identification**, **data capture** (**barcoding**), **aggregation**, **and data exchange** informed by the business need and/or challenge the country wishes to address through track and trace



PRODUCT SCOPE – which products are subject to the regulation



DATA CAPTURE – how identification data should be encoded in data carriers on specific packaging levels



items and logistics units must be uniquely identified that enter the market/ supply chain



DATA EXCHANGE – what data must be exchanged

Centralized National Track & Trace Approach

Process Consideration

Countries may use the GS1 EPCIS standard for exchanging traceability event data in a way that enables traceability events to be communicated. Countries will have to decide what events need to be recorded for their track and trace system to meet requirements. The table below illustrates key EPCIS events related to track and trace and the party responsible for performing the functions in a chain-of-custody model

	WHAT objects are the subject of this event (GTIN + serial number = sGTIN)	WHERE this occurred and where the objects went after that GLN of physical location	WHEN this event took place	WHY this event took place
Manufacturer	Allocate and retain sGTIN for item	Record GLN where the item/ cases/ pallet was commissioned	Record the date and time of commissioning the item	Commission Aggregation
Wholesalers / Distributors / Warehouses	Assign and record SSCC of pallet, Record package (sGTIN) Transaction Information & Transaction History, and Transaction Statement	Record GLN of ship-to-party Record transferring ownership of the product	Record the date and time of shipment of package / shipment receipt and transfer to next location	Receiving Disaggregation Aggregation Shipping
Healthcare facilities	Record package (sGTIN) Transaction Information & Transaction History, and Transaction Statement Decommission sGTIN	Record GLN of service delivery point Record "ship-from" GLN	Record date and time package was received	Receiving Dispensing Disaggregation Decommission

The illustrative What, Where, When, and Why of traceability events

Centralized National Track & Trace Approach

Technology Consideration

Supply chain stakeholders must be able to capture and exchange product event and transactional data with a central database. To achieve this, each stakeholder must have the following technological capabilities:

- Systems capable of capturing data scanned from 1D and 2D data carriers at the trade item secondary and tertiary pack levels
- Supply chain systems able to send and receive transactional data electronically to and from supply chain participants, such as vendors, warehouses, and facilities
- Ability to manage event data exchanged using the GS1 EPCIS standard
- Technology to capture an event and associate it with a specific item and entity through GTIN and GLN, respectively
- Systems that enable aggregation and disaggregation of serial numbers as logistics units are dismantled and/or repackaged through the supply chain

Government

Government Reporting Supply Chain Integration End user authentication (e.g. Mobile Apps)

Level 5: Network System





S/N 255





Enterprise

Enterprise Serial Manager Enterprise Serialized Repository ERP

Level 4: Enterprise System





Plant & Distribution Centre

Plant Serial Manager Configuration Management Local Serialized Repository Rework & Returns WMS/ Shipment event capture

Level 3: Site Control System







Batch configuration
Serialized event capture
Reconciliation & Reporting
Line automation
Camera/ Scanners
Printers Label artwork

Level 2: Packaging Line Automation

Level 1: Devices











System Requirement (Hardware & Software) – Industry & Government

Pharmaceutical Track & Trace System



Track & Trace Model

Centralized National Track & Trace Approach



Track & Trace MOH Malaysia Perspective

Objective: Traceability & Visibility, Supply Chain Security & Efficiency, Combat Substandard & Falsified Medicine & Unregistered Products and Patient Safety


PRODUCT SCOPE



All registered product (A,X,T,N)*


*Implementation in phases

PACKAGING LEVELS & AGGREGATIONS



Saleable Unit Tertiary Packaging Aggregations

DATA CARRIER & ELEMENTS



GS1 2D DataMatrix

- GTIN
- Expiry date
- Lot/ batch number
- Serial Number

DATA EXCHANGE & DATABASE



& Trace System
GS1 EPCIS Standard

FULL TRACEABILITY; END-TO-END MODEL



Factors Affecting Track & Trace Implementation







Political

Contextual Factors

Government support and action

The absence of mandate from the government may lead to fragmented implementation

Legislation and regulation

Well-defined legislation and regulation eased the implementation

Social

Contextual Factors

Supply chain actor support

Costs of implementation, complexity of legislation & incentives

Awareness, **knowledge** and **skill**

Support by training, preparation & timeline

Economical

Contextual Factors


Investment

Money, time & effort – adhere to compliance


Technical and digital capacities

ICT infrastructure, choice of system and technology, system integration, adjustability of system, agile methodology

Implementation Progress: (2017 - 2022)



Track & Trace Proof of Concept (POC)




Dispense


Vaccinee

COVID-19 Vaccination


Track & Trace Proof of Concept (POC)



Track & Trace Proof of Concept (POC)



Track & Trace Proof of Concept (POC)



Track & Trace Proof of Concept (POC)

Gap Analysis

*NPRA, November 2021

#	ltem	VMS	Track & Trace (to be)
1.	Product	COVID-19 vaccine (18 types & variants)	All registered product* (A,XT,N): Scheduled poison (7,317), Non-poison (2,597), Health Supplement (2,307), Traditional (12,900)
2.	Serialization	Serialization number generated by VMS	Serialized GTIN (sGTIN): GTIN, Lot, Expiry & Serialization Number
3.	Packaging levels	PKU/ Unit box/ Secondary packaging	Secondary Packaging/ Saleable unit, aggregation
4.	System integration	PhIS, CPS, MyVAS, MySejahtera	QUEST, ERP, WMS, HIS, PhIS&CPS, POS, other relevant agencies
5.	Activity/ Process	Absence of activity: aggregation, decommission	GS1 EPCIS Standard; Commissioning, Aggregation, Shipping, Receiving, Disaggregation, Dispensing, Decommission, etc.
6.	Database	Government-own	Government-own
7.	Stakeholders	End-to-end (COVID-19 vaccine only)	End-to-end (all registered product)
8.	Patient Data	Vaccinee information	Absence of patient/ consumer information

Pharmaceutical Track & Trace System

Pilot Project

The proposal was presented and notified by the Drug Control Authority (DCA) 374th Meeting on July 7th, 2022

- i. Improving the existing Security Label (Hologram) System
- ii. Standard data carrier consisting of unique ID (UID) on every product for identification and verification
- iii. Scanning of UID capture and record defined activities related to product

Mechanism of Implementation

Two (2) choices of data carrier (GS12D DataMatrix or FamaTag)

Stakeholders Engagement

Continuous engagement with stakeholders

Development of Track & Trace System(Database/ Repository)

Type of Product

Vaccine listed under the National Immunisation Programme (NIP)

Pilot Project Reporting

Development of Track & Trace implementation Guideline

Commencement of Pilot Project: Jan 2023 to June 2023



PEJABAT PENGARAH KANAN PERKHIDMATAN FARMASI
OFFICE OF THE SENIOR DIRECTOR OF PHARMACEUTICAL SERVICES
Kementerian Kesihatan Malaysia

Lot 36, Jalan Prof Diraja Ungku Aziz, Petaling Jaya 46200 SELANGOR

Faks: 03-7968 2222 Laman Web: www.pharmacy.gov.my E-mel: pejabatpkpf@moh.gov.my

POS BERDAFTAR

Rui. Kami

: NPRA.600-1/9/7 (40) Jid-1

Tarikh

: 1 Julai 2022

SEMUA PEMEGANG PENDAFTARAN

SEMUA PERSATUAN BERKENAAN (SEPERTI DI SENARAI EDARAN)

Tuan / Puan.

PELAKSANAAN PROJEK RINTIS PHARMACEUTICAL TRACK & TRACE

Dengan hormatnya saya merujuk kepada perkara tersebut di atas.

- Pihak Berkuasa Kawalan Dadah (PBKD) melalui mesyuaratnya kali ke-374 pada
 Julai 2022 telah mengambil maklum berkenaan perkara berikut :
 - 2.1 Kerajaan sedang membangunkan sistem Pharmaceutical Track & Trace yang meliputi keseluruhan rantaian bekalan (end-to-end) bermula dari Pemegang Pendaftaran Produk (PRH)/ pengilang/ pengimport sehingga ke peringkat pengguna akhir (end user).
 - Projek rintis akan dilaksanakan selama 6 bulan dan dijangka bermula Januari 2023 hingga Jun 2023.
 - Sesi libat urus bersama semua pemegang taruh yang terlibat dengan projek rintis akan dijalankan sebelum projek dilaksanakan.

Pharmaceutical Track & Trace System

Pilot Project

Type of Product

Vaccines (imported & locally manufactured) listed under the National Immunization Programme: (BCG, Diphteria&Tetanus, Haemophilus Influenza Type B, Hepatits B, Measles, MMR, Meningococal & Typhoid)
Other products TBC

Rationale:

- (i) **Cold chain item** well controlled environment and stakeholders' involvement
- (ii) **Stakeholders** identify, engagement session, training, system integration & requirement
- (iii) Align with digitalization of vaccine certificate by the Public Health Programme MOH Malaysia

Data Carrier

- (i) GS1 2D DataMatrix (direct serialization on packaging)
- (ii) Hologram FarmaTag™

Rationale:

- (i) Implementation of track & trace by phases voluntary & mandatory phases by category of product
- (ii) **During voluntary phases** both GS1 2D DataMatrix and Hologram will be used; to study the impact, issues & challenges, feedback from stakeholders and feasibility of system & implementation
- (iii) Stakeholders' readiness and sufficient timeline for mandatory phases

Mechanism of Implementation

Pilot Project Pharmaceutical Track & Trace System

Two (2) choices of data carrier:



Serialized GTIN (sGTIN): GTIN, Lot, Expiry & Serialization Number

OR



Product's data submission and commissioning; upload into Authority's Centralized Track & Trace System as follows:

	GS1 2D DataMatrix	Hologram FarmaTag™
Imported Product	Direct serialization from country of origin OR by licensed premises in Malaysia	Import license holder shall: • Apply Hologram FarmaTag™ on packaging
	 Data submission and commissioning shall be implemented 	 Carry out product data assignment for every hologram security label applied on packaging
Locally Manufactured	 Direct serialization by the manufacture (in-house process) 	 Manufacturing license holder shall: Apply Hologram FarmaTagTM on packaging
Product	 Manufacturing license holder shall carry out <i>Data</i> submission and commissioning 	 Carry out product <i>data assignment</i> for every hologram security label applied on packaging


End-to-end (every stakeholders at all level of supply chain)




Capture data and record defined activities related to product

Timeline

Pilot Project Track & Trace





Pending:

Sept

- (i) Appointment of solution provider to develop Track & Trace
- ii) Stakeholders' engagement after the appointment of solution provider

Jan			
Feb			
Mar	Implementation of Track & Trace		
Apr	Pilot Project		
May			
Jun			
Jul	Pilot Project Report & Implementation Guideline		
Aug	Pilot Project Report in DCA Meeting & DCA Directives on Track & Trace Implementation		
Sont	Commencement of Track & Trace implementation		

in phases (scheduled poison)

(Potential) Issues & Challenges

Pilot Project Pharmaceutical Track & Trace System

Operational Efficiency

Operational efficiency lost is observed while switching to serialized warehouse operations.

Efficiency recovers over time when systems and operations stabilized but maybe not to the original efficiency levels

Cost

Serialized operations incurs additional cost especially for logistics operations outsourced to 3PL

Technology

Investment in information system and equipment upgrade is required in supporting integration with sterilization management systems.

Good Distribution Practice (GDP)

Instead of managing inventory by quantity, it is necessary to track by individual unit. Scanning and validation of serial numbers in each step is required to ensure data accuracy and capture product movement of individual units for compliance.

Operations are no longer only managing the physical product as GDP. Now operations has to manage the physical product and also the parallel data both as GDP.

Stakeholders: Authority, Industry, Healthcare Facilities & Consumer


Moving Forward

Pharmaceutical Track & Trace System

- Using lessons learned and leveraging from past experiences
- <u>Promoting pilots</u> and tests in case of new regulatory needs or purposes
- Focusing on collaboration and always keeping open dialogue
- Starting simple, gathering learnings and evolving

(Projected) Timeline

Full Implementation Pharmaceutical Track & Trace System



THANK YOU

Track & Trace:

Implementation Plan & Updates

Pharmaceutical Services Programme, Ministry of Health Malaysia

References:

- (i) Sale of Drugs Act 1952 (revised 1989) & Control of Drugs and Cosmetics Regulations 1984 (revised 2006)
- (ii) Drug Registration Guidance Document (DRGD), January 2022, National Pharmaceutical Regulatory Agency (NPRA)
- (iii) Policy paper on traceability of medical products. Geneva: World Health Organization; 2021.
- (iv) Malaysian National Medicines Policy, Ministry of Health Malaysia 3rd Edition (2017-2021).
- (v) Twelfth (12th) Malaysian Plan (2021-2025), Economic Plan Unit, Prime Minister Department, 2021.
- (vi) Pelan Strategik Pendigitalan, Kementerian Kesihtan Malaysia, 2021.
- (vii) Pelan Strategik Kementerian Kesihatan Malaysia (2021-2025)
- (viii) Quick Guide Key Consideration for Centralized National Pharmaceutical Traceability Approaches, USAID Global Health Supply Chain Program.
- (ix) Kootsra J, Kleinhout-Viek T. Implementing pharmaceutical track-and-trace systems: a realist review. BMJ Global Health 2021.
- (x) CK Lam, Serialization and traceability as well as challenges and impact on GDP, Pfizer Inc., 2021.
- (xi) Olivera, L., Global Regulatory Evolution for Product Serialization and Traceability, Johnson & Johnson, 2019